Back to User profile » Dr Angela Märten
Papers published by Dr Angela Märten:
![Plain language summary](assets/img/article_icons/plain-language.png)
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P
OncoTargets and Therapy 2024, 17:267-280
Published Date: 29 March 2024
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies
![](cr_data/cache/article_graphical_abstract/s362535/graphical_abstract.jpg)
Miura S, Jung HA, Lee SY, Lee SH, Lee MK, Lee YC, Hochmair MJ, Yang CT, Märten A, Yang JCH, Popat S
OncoTargets and Therapy 2022, 15:873-882
Published Date: 22 August 2022
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/IIG8Om9qlkc/1.jpg)
Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C
OncoTargets and Therapy 2018, 11:8575-8587
Published Date: 30 November 2018